Insights about U.S. Stocks that landed in the Red-Zone during Tuesday’s trade, are depicted underneath:

Kite Pharma Inc (NASDAQ:KITE)’s shares dwindled - 4.13%, and closed at $61.47, during the last trading session.

Kite Pharma, Inc. (KITE), a clinical-stage biopharmaceutical corporation focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, recently declared that the Corporation has amended its Cooperative Research and Development Contract (CRADA) with the National Cancer Institute (NCI). The amendment will encompass emerging areas of research in the immune response to tumor neo-antigens, truly tumor-specific antigens generated as tumors accumulate genetic mutations. In addition, new T cell receptor (TCR) and new chimeric antigen receptor (CAR) product candidates targeting solid tumors have been added to the collaboration. The amendment broadens Kite’s ongoing research partnership with the Surgery Branch at the NCI, led by Steven A. Rosenberg, M.D., Ph.D. and provides additional product candidates for Kite’s growing pipeline.

Under Kite’s amended contract with the NCI, the additional programs will encompass:

• Methods of rapidly identifying and developing TCR product candidates targeted against neo-antigens.
• Optimizing new methods to manufacture this new class of individualized therapies.
• Developing additional TCR product candidates retrovirally engineered to target tumor antigens, counting for the treatment of colorectal and lung cancers.

Kite Pharma, Inc. operates a clinical-stage biopharmaceutical corporation which focuses on the development and commercialization of novel cancer immunotherapy products.

Caesars Entertainment Corp (NASDAQ:CZR), declined -3.99%, and closed at $10.58.

Caesars Entertainment Corporation (CZR),stated the following fourth quarter and full year 2014 results and recent developments:

• Merged net proceeds raised 6% year-over-year driven by growth at CGP LLC and CERP
• Merged results led by strength in social and mobile games and new hospitality offerings were offset by unfavorable hold at Caesars Palace and raised operating expenses
• CEOC declared comprehensive debt restructuring plan on December 19, which comprises a noteworthy reduction in CEOC’s long-term debt and annual interest payments
• Caesars Attainment Corporation and Caesars Entertainment declared on December 22 an contract to merge in a combined corporation that will be positioned for sustainable long-term growth and value creation.

Caesars Entertainment Corporation owns, operates, or manages casino entertainment facilities. Its casino entertainment facilities comprise land-based casinos, riverboat or dockside casinos, and managed casinos, in addition to casinos combined with a thoroughbred racetrack and a harness racetrack.

Novavax, Inc (NASDAQ:NVAX) dipped - 3.92%, and closed at $8.57.

Novavax, Inc. (NVAX), a clinical-stage vaccine corporation focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, formerly on February 26, declared its financial results for the fourth quarter and twelve months ended December 31, 2014.

Fourth Quarter and Subsequent Achievements:

RSV

• Initiated a Phase 2 clinical trial of its RSV F-Protein nanoparticle vaccine candidate (RSV F Vaccine) in 1,600 elderly adults (>=60 years of age);
• Received the U.S. Food and Drug Administration’s (FDA) Fast Track Designation of our RSV F Vaccine for protection of infants via maternal immunization, which, among other advantages, provides the potential for priority review (shorter Biologics License Application review) that could result in improved timeline to licensure;
• Initiated enrollment in a Phase 1 clinical trial of our RSV F Vaccine in healthy children, the first study of this vaccine candidate to be conducted in a pediatric population; and
• Presented new positive data from the first clinical study of our RSV F Vaccine in women of childbearing age at the 8th Vaccine & ISV Congress, showing 50% reduction in infection in the vaccinated women relative to placebo. This data suggests that the vaccine may be efficacious in future clinical testing.

Novavax, Inc., a clinical-stage biopharmaceutical corporation, focuses on discovering, developing, and commercializing recombinant protein nanoparticle vaccines and adjuvants.

Venaxis Inc (NASDAQ:APPY) dropped –2.70%, and closed at $0.540. The company has the market capitalization of $18.14M. The beta value of the stock is 1.31. On the other hand the stock’s volatility for the week is 12.40%, and for the month is 10.61%. The stock price to book value is $0.64, however price to sale value is $187.65. Analyst’s mean recommendation regarding this stock is 3.00. (where 1=Buy, 5=Sale).

Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. The corporation’s research and development activities primarily focus on a human acute appendicitis blood-based test.